Home Healthcare IT Anti-VEGF Therapeutics Market Size, Share & Growth Graph by 2034

Anti-VEGF Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu, Vabysmo, Others), By Disease Type (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Myopic Choroidal Neovascularization) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Report Code: SRHI54734DR
Last Updated: Mar, 2026
Pages: 150
Author: Debashree Bora
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Anti-VEGF Therapeutics Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    4. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
        5. Vabysmo
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
        6. Myopic Choroidal Neovascularization
          1. By Value
    5. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    4. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
        5. Vabysmo
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
        6. Myopic Choroidal Neovascularization
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    4. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
        5. Vabysmo
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
        6. Myopic Choroidal Neovascularization
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    4. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
        5. Vabysmo
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
        6. Myopic Choroidal Neovascularization
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Eylea
        1. By Value
      3. Lucentis
        1. By Value
      4. Beovu
        1. By Value
      5. Vabysmo
        1. By Value
      6. Others
        1. By Value
    3. By Disease Type
      1. Introduction
        1. Disease Type By Value
      2. Macular Edema
        1. By Value
      3. Diabetic Retinopathy
        1. By Value
      4. Retinal Vein Occlusion
        1. By Value
      5. Age-related Macular Degeneration
        1. By Value
      6. Myopic Choroidal Neovascularization
        1. By Value
    4. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Eylea
          1. By Value
        3. Lucentis
          1. By Value
        4. Beovu
          1. By Value
        5. Vabysmo
          1. By Value
        6. Others
          1. By Value
      2. By Disease Type
        1. Introduction
          1. Disease Type By Value
        2. Macular Edema
          1. By Value
        3. Diabetic Retinopathy
          1. By Value
        4. Retinal Vein Occlusion
          1. By Value
        5. Age-related Macular Degeneration
          1. By Value
        6. Myopic Choroidal Neovascularization
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Anti-VEGF Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Regeneron Pharmaceuticals, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bayer AG
    3. Novartis AG
    4. Hoffmann-La Roche Ltd.
    5. Frensius Kabi
    6. Biogen
    7. Pfizer, Inc.
    8. Alvotech
    9. Teva Pharmaceuticals
    10. Coherus Biosciences, Inc.
    11. Amgen, Inc.
    12. Bausch Health Companies, Inc.
    13. Viatris, Inc.
    14. Sanofi
    15. Isarna Therapeutics
    16. Genentech
    17. SamChunDang Pharm
    18. Roche
    19. Formycon AG
    20. Bioeq AG
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Straits Research
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.